ALVO vs. QGEN, VTRS, ASND, MRNA, BBIO, BPMC, VRNA, ROIV, ELAN, and RVMD
Should you be buying Alvotech stock or one of its competitors? The main competitors of Alvotech include Qiagen (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), Moderna (MRNA), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry.
Alvotech vs. Its Competitors
QIAGEN (NYSE:QGEN) and Alvotech (NASDAQ:ALVO) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.
QIAGEN has higher revenue and earnings than Alvotech. Alvotech is trading at a lower price-to-earnings ratio than QIAGEN, indicating that it is currently the more affordable of the two stocks.
70.0% of QIAGEN shares are owned by institutional investors. 9.0% of QIAGEN shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Alvotech has a net margin of 16.42% compared to QIAGEN's net margin of 4.68%. QIAGEN's return on equity of 14.61% beat Alvotech's return on equity.
In the previous week, Alvotech had 4 more articles in the media than QIAGEN. MarketBeat recorded 9 mentions for Alvotech and 5 mentions for QIAGEN. Alvotech's average media sentiment score of 0.97 beat QIAGEN's score of 0.33 indicating that Alvotech is being referred to more favorably in the news media.
QIAGEN has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, Alvotech has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500.
QIAGEN currently has a consensus target price of $49.40, suggesting a potential upside of 4.02%. Alvotech has a consensus target price of $18.00, suggesting a potential upside of 99.56%. Given Alvotech's stronger consensus rating and higher probable upside, analysts plainly believe Alvotech is more favorable than QIAGEN.
Summary
QIAGEN beats Alvotech on 9 of the 16 factors compared between the two stocks.
Get Alvotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ALVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alvotech Competitors List
Related Companies and Tools
This page (NASDAQ:ALVO) was last updated on 7/7/2025 by MarketBeat.com Staff
